BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11442658)

  • 1. Prognostic factors for survival and bladder recurrence in transitional cell carcinoma of the upper urinary tract.
    Morioka M; Jo Y; Furukawa Y; Kinugawa K; Sone A; Matsuki T; Kobayashi T; Fujii T; Tanaka H
    Int J Urol; 2001 Jul; 8(7):366-73. PubMed ID: 11442658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
    Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
    Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients.
    Hall MC; Womack S; Sagalowsky AI; Carmody T; Erickstad MD; Roehrborn CG
    Urology; 1998 Oct; 52(4):594-601. PubMed ID: 9763077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of primary transitional cell carcinoma of the upper urinary tract.
    Lee SH; Lin JS; Tzai TS; Chow NH; Tong YC; Yang WH; Chang CC; Cheng HL
    Eur Urol; 1996; 29(3):266-70; discussion 271. PubMed ID: 8740029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ.
    Takashi M; Wakai K; Hattori T; Furuhashi K; Ono Y; Ohshima S; Ohno Y
    Int Urol Nephrol; 2002; 33(1):41-7. PubMed ID: 12090337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC; Lin AT; Chen KK; Chang LS
    Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; Li ML
    Jpn J Clin Oncol; 2004 Apr; 34(4):202-5. PubMed ID: 15121756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
    de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
    J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.